Tislelizumab plus chemotherapy and radiotherapy yields 89.1% 3-year disease-free survival in pMMR/MSS locally advanced rectal cancer
Early trial shows high survival rates for rectal cancer patients treated with tislelizumab
This Phase 2 clinical trial evaluated neoadjuvant tislelizumab, chemotherapy, and long-course radiotherapy in 50 patients with pMMR/MSS loca…
A Phase 2 trial found that adding tislelizumab to standard care helped 89% of patients stay free of cancer for three years. This approach wo…
MRI-derived nomogram improves high-risk LARC stratification over single-feature models in a multicenter retrospective cohort
New MRI Tool Pinpoints Which Rectal Cancer Patients Need Intensive Treatment
This multicenter retrospective cohort study evaluated a nomogram integrating habitat heterogeneity, peritumoral (3 mm) radiomic features, an…
This new approach could spare some patients from harsh treatments while ensuring others get the aggressive care they need.
Neoadjuvant CAPOX chemotherapy alone showed comparable survival to chemoradiotherapy in locally advanced rectal cancer with uninvolved mesorectal fascia
Some Rectal Cancer Patients May Skip Radiation Without Losing Ground
This Phase III RCT compared 4 cycles of CAPOX chemotherapy alone versus chemoradiotherapy in patients with locally advanced rectal cancer an…
Some rectal cancer patients can skip pre-surgery radiation and still achieve similar cure rates while avoiding long-term side effects like b…
Dynamic ctDNA monitoring during neoadjuvant chemotherapy identifies high-risk rectal cancer patients
Blood test during chemo may help predict rectal cancer treatment response
A biomarker substudy of a multicenter RCT in 153 patients with low-/intermediate-risk locally advanced rectal cancer found that dynamic ctDN…
A blood test tracking tumor DNA during chemo can predict which rectal cancer patients won't respond well to treatment before surgery.
Phase 2 trial tests metformin with neoadjuvant radiochemotherapy for locally advanced rectal cancer
Could a common diabetes drug help people with rectal cancer respond better to treatment?
A Phase 2 trial (n=60) evaluated adding metformin to neoadjuvant radiochemotherapy (capecitabine + 50 Gy radiation) for locally advanced rec…
Adding a common diabetes pill to pre-surgery treatment for rectal cancer may help clear out cancer cells before the operation begins.
Research across Microsatellite-stable colorectal cancer
Related studies from across the Microsatellite-stable colorectal cancer family.
Closing rectal wall defects after full-thickness excision reduces bleeding and re-admission rates compared to leaving defects open in patients with rectal neoplasms
Closing the rectal wall defect lowers bleeding and re-admission rates after surgery
A systematic review and meta-analysis of six studies found that closing rectal wall defects after full-thickness excision significantly lowe…
A review of six studies found that closing the rectal wall defect after surgery significantly reduced bleeding and re-admission rates compar…
ESD achieves R0 resection for large rectal intramucosal carcinoma involving dentate line in case report
Imagine a large, pre-cancerous growth in the most sensitive part of your rectum. Removing it used to mean major, life-altering surgery. But a new report shows a different path is possible
A case report describes a 70-year-old male with altered bowel habits who underwent endoscopic submucosal dissection for a large rectal tumor…
Doctors successfully removed a large, tricky rectal tumor with a minimally invasive technique, preserving the patient's natural bowel functi…
Questions about Locally Advanced Rectal Cancer
What specific radiomic features does the new MRI model use to stratify risk?
The new MRI model uses intratumoral habitat heterogeneity features (from K-means clustering) and peritumoral radiomic features from 1, 2, and 3 mm margins around the tumor.
Full answer →Can an MRI nomogram help predict if my locally advanced rectal cancer is high-risk?
Yes, an MRI nomogram that combines habitat radiomics and clinical factors can predict high-risk LARC more accurately than single-feature models, helping guide treatment decisions.
Full answer →